contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


annual-report-2022-active-biotech-ab-publ

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Active Biotech är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för cancer och autoimmuna sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Projektportföljen omfattar både små, oralt aktiva immunmodulerande molekyler samt antikroppsbaserad immunterapi. Bolaget är verksamt globalt. Active Biotech grundades 1998 och har sitt huvudkontor i Lund.

Active Biotech

Active Biotech's Annual Report 2022 is now available for download at www.activebiotech.com.The Annual Report will only be digitally distributed.For further information, please contact:Helén ...

<div class="mfn-body"><p>Active Biotech's Annual Report 2022 is now available for download at <a rel="noopener" href="http://www.activebiotech.com">www.activebiotech.com</a>.</p><p>The Annual Report will only be digitally distributed.</p></div><div class="mfn-footer mfn-contacts mfn-39926fa7db58"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Helén Tuvesson,&nbsp;<em>CEO</em>, +46 46 19 21 56, <a rel="noopener" href="https://www.globenewswire.com/Tracker?data=iFG1kvVIp5pKUTaCk0JiGzw9dl5sOO_9c1qJkW85IwkJ2q3yfKNYaxNkYx6dheJqlz7uzyshFUzqp1r58eX0EwmkE0v707I8o0lPBbqYY8UvgU199yEyZAn5dlfWfZO4">helen.tuvesson@activebiotech.com</a><br>Hans Kolam,&nbsp;<em>CFO</em>, +46 46 19 20 44,&nbsp;<a rel="noopener" href="https://www.globenewswire.com/Tracker?data=MR5_ToeY_jOzyHsukO6TttPqhmPsAbWR4pvo7PzeBD-PVZpENlc1ykgW0p6jbew_WmkeAMSZFzoNVxkl8nuvvBVhljBcYy9uABVnK5yHhZKIfjtRDFjP5TNN-jwbPdiWCxnYxOQCr1gRU1L5udq8QNYq3vgqNIrmfSf1E8uCbUY4kMhRORUZ0ZdijKi9A-QPkK6sbjrvP0yHKc0XZwaRAWbewx1p63FAFCock9Mybrm3wdpGuMxvELcnTuccE0HQF7XVdn4dPrJgjbA4Z0m7IkCDp1nqkpJod1DlYbgCbuA=">hans.kolam@activebiotech.com</a></p></div><div class="mfn-footer mfn-about mfn-4dca1f9d12f2"><p><strong class="mfn-heading-1">About Active Biotech</strong></p><hr><p><strong>Active Biotech AB (publ) (NASDAQ Stockholm: ACTI)</strong> is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit&nbsp;<a rel="noopener" href="http://www.activebiotech.com/en/">www.activebiotech.com</a>&nbsp;for more information.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-vpml"><p><em>This information is information that Active Biotech is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-26 15:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/077d137f-3327-4e48-8092-fc794bdd54e6/active-biotech-2022-eng.pdf" class="mfn-primary">Active Biotech 2022 Eng</a></p></div>